Medical/Pharmaceuticals

Cell Publishes Breakthrough Research Results of IASO Bio's Anti-BCMA CAR-T Equecabtagene Autoleucel in Autoimmune Disease Multiple Sclerosis

SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 16, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that theCell published results fr...

2025-10-16 20:45 1654

Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025

SHANGHAI, Oct. 16, 2025 /PRNewswire/ -- Unixell Biotech, a clinical-stage bitotech company focused on developing innovative cell therapies for Parkinson'sdisease (PD) and other neurological disorders, announced positive 6-month follow-up data from the first patient in its phase 1 clinical trial ...

2025-10-16 20:35 1456

SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology

BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients t...

2025-10-16 16:01 1113

HARMONi-6 Phase III Study of Ivonescimab Accepted by The Lancet and Selected for ESMO 2025 LBA Presentation

HONG KONG, Oct. 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that the groundbreaking results from the registrational Phase III AK112-306/HARMONi-6 study of ivonescimab have been accepted for publication in The Lancet. The study evaluated ivonescimab, a first-in-class PD-1/VEGF b...

2025-10-16 12:15 1483

Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights

At ASHG, an early access customer from the London Health Sciences Center Research Institute demonstrated the power of the 5-base genome for accelerating resolution of rare disease cases  Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry,providing researchers with ...

2025-10-16 11:43 1047

ROSTI partners with IDC to bring innovative medical device design and manufacturing capabilities

SHANGHAI, Oct. 16, 2025 /PRNewswire/ -- A report from Ringiertrade. MedTec China 2025, which took place at the Shanghai World Expo Exhibition & Convention Center (SWEECC) fromSeptember 24-26, served as the ideal platform to promote the latest innovations in the production of medical devices. At t...

2025-10-16 11:30 1323

Gene Solutions Brings Insights on Advances in MRD and Multi-Omics Technologies to the Singapore Society of Oncology Annual Scientific Meeting 2025

SINGAPORE, Oct. 15, 2025 /PRNewswire/ -- What if cancer care could move from reactive to proactive? At the Singapore Society of Oncology Annual Scientific Meeting 2025 (SSO ASM 2025),Gene Solutions showcased how Molecular Residual Disease (MRD) and AI-powered multi-om...

2025-10-16 10:30 2189

DKSH Reinforces Patient-Centric Commitment with "Patient Purpose Day 2025", Spotlighting Women's Health Equity

DKSH Business Unit Healthcare continues bringing patient centricity to life with "Patient Purpose Day 2025". This global initiative, held for the third consecutive year across 12 markets across APAC andSwitzerland, reinforces DKSH's dedication to improving patient outcomes. This year, the program...

2025-10-16 10:00 871

PENTAX Medical Announces Sale of C2 CryoBalloon™ Product Line to Merit Medical Systems through Asset Purchase Agreement

Transaction supports PENTAX Medical's strategic focus on core flexible reusable endoscopy MONTVALE, N.J., Oct. 16, 2025 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group and a global leader in flexible reusable endoscopy, today announced an asset purchase agreement with Merit Medical Syst...

2025-10-16 04:05 1464

Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline

BEIJING and SHANGHAI and BOSTON, Oct. 15, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry part...

2025-10-15 23:05 2576

TriNetX Becomes the Most Cited Real-World Data Source in Peer-Reviewed Research

With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top medical journals.  CAMBRIDGE, Mass., Oct. 15, 2025 /PRNewswire/ -- TriNetX, driven by its vision of a connected world where data and intelligence powe...

2025-10-15 20:34 1497

SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia

* Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses * Phase 1/2 study to enroll ~500 healthy adults, with topline results expected by 2028 * We aim to build a universal Sarbecovirus vaccine platform to proactively address future pandemics SEONGNAM, South Kor...

2025-10-15 20:00 2041

Tamarind Health Marks Next Phase as Asia's Leading Integrated Oncology Platform

SINGAPORE, Oct. 15, 2025 /PRNewswire/ -- Tamarind Health marks the next phase in its growth asAsia's leading integrated oncology-focused healthcare platform, following the completion of its acquisition of TalkMED inSeptember 2025. A doctor-led platform built on the principle of putting patients f...

2025-10-15 17:01 1144

Sinocare Showcases Its Comprehensive Diabetes Management Solutions at EASD

VIENNA, Oct. 15, 2025 /PRNewswire/ -- The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD 2025) was successfully held in Vienna, Austria. During the conference, Sinocare hosted an international industry symposium and an exclusive networking dinner, fully demonstrati...

2025-10-15 14:34 1471

Safex Chemicals India Ltd. Receives Frost & Sullivan's 2025 Global Competitive Strategy Leadership Recognition for Excellence in Crop Protection Chemicals

Safex earns global recognition for its innovation-driven strategy, digital transformation, and customer-centric approach in the evolving crop protection chemicals industry. SAN ANTONIO, Oct. 15, 2025 /PRNewswire/ -- Frost & Sullivan

2025-10-15 14:00 1150

At the World Congress of Neurology, WHO Outlines a Global Roadmap to Make Brain Health a Universal Reality

SEOUL, South Korea and LONDON, Oct. 15, 2025 /PRNewswire/ -- Neurological conditions now affect more than 40% of the population—over 3 billion people, according to WHO's Global Status Report on Neurology, released at the World Congress of Neurology (WCN) inSeoul. The report reveals that neurolog...

2025-10-15 13:32 1029

Nona Biosciences Appoints Dr. Di Hong as Chief Executive Officer to Drive Technology Innovation and Strategic Growth

CAMBRIDGE, Mass., Oct. 14, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), today announced the appointment of Dr. Di Hong as Chief Executive Officer (CEO). Dr. Hong will be based inShangh...

2025-10-15 08:00 1320

Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical research results of its novel B7-H3-targeting ADC (R&D code: 7MW3711) for multiple advanced solid tumors, will be presented as a poster at the E...

2025-10-15 00:00 2585

Co-PSMA trial achieves primary endpoint

SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT...

2025-10-14 21:03 2595

Lunit AI Predicts Immunotherapy Outcome in Colorectal, Kidney, and Lung Cancer at ESMO 2025

AI-powered histopathology demonstrates predictive value for immunotherapy outcomes in pMMR mCRC, advanced ccRCC, and NSCLC with data featured in both oral and poster presentations SEOUL, South Korea, Oct. 14, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnos...

2025-10-14 21:00 1150
1 ... 43444546474849 ... 645

Week's Top Stories